Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut ...
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse ...
Le Lézard8 日
Metaba and MAX BioPharma Announce Breakthrough Progress on Next-Generation Oxysterol-Based ...
Metaba, LLC ( and MAX BioPharma, Inc. ( are pleased to announce significant progress in their collaboration to develop oxysterol-based drug candidates targeting bacterial pathogens. This pioneering ...
Pharmabiz11 日
Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent
Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...
Channel 300012 日
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
(NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics ... for potential oral and parenteral use in multiple clinical ...